Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP2DNS)

Drug Name

Rambazole Drug Info

Synonyms

Talarozole; 201410-53-9; R-115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)benzo[d]thiazol-2-amine; R115866; CHEMBL459505; C21H23N5S; Rambazole (TN); Talarozole (USAN/INN); Talarozole [USAN:INN]; R 115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)-2-benzothiazolamine; Talarozole pound> SCHEMBL721201; CHEBI:102167; MolPort-018-666-712; SNFYYXUGUBUECJ-UHFFFAOYSA-N; BCP28256; BCP21218; BDBM50253810; 0328AB; AKOS005067289; DB13083; CS-1343; NCGC00378894-01; HY-14531; AX8224298; D09385; W-5674; MEN13510

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Phase 2	[1]
Asthma	CA23	Investigative	[2]

Cross-matching ID

PubChem CID: 9799888
ChEBI ID: CHEBI:102167
CAS Number: CAS 201410-53-9
TTD Drug ID: DMP2DNS

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Substance-K receptor (TACR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibodutant	DMT67EH	Irritable bowel syndrome	DD91.0	Phase 3	[3]
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[4]
Nepadutant	DMPMF6L	Infantile colics	DD93.1	Phase 1/2	[5]
Saredutant	DMSRJY3	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 3	[6]
CS-003	DM1AEVT	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[7]
FK-224	DM1JUS0	Asthma	CA23	Discontinued in Phase 2	[8]
DNK-333	DM4ZO01	Irritable bowel syndrome	DD91.0	Discontinued in Phase 2	[9]
AVE-5883	DM3P84V	Asthma	CA23	Discontinued in Phase 1/2	[10]
UK-224671	DMDTRJB	Urinary incontinence	MF50.2	Discontinued in Phase 1	[11]
SR 144190	DMK4XT8	Acute or chronic pain	MG30-MG31	Discontinued in Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Cytochrome P450 26 (CYP26A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LIAROZOLE	DM4OYXE	Dermatological disease	DA24.Y	Phase 2/3	[13]
4-((+/-)-(1H-imidazol-1-yl)-(E)-methylretinoate	DMI15VQ	Discovery agent	N.A.	Investigative	[14]
4-((+/-)-(1H-imidazol-1-yl)-(E)-retinoic acid	DMKYB4D	Discovery agent	N.A.	Investigative	[14]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytochrome P450 26 (CYP26A1)	TTD7Q0R	CP26A_HUMAN	Inhibitor	[1]
Substance-K receptor (TACR2)	TTYO0A3	NK2R_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
2	Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor. Eur J Pharmacol. 2005 Jun 1;516(2):104-11.
3	Antagonist profile of ibodutant at the tachykinin NK2 receptor in guinea pig isolated bronchi. Eur J Pharmacol. 2013 Nov 15;720(1-3):180-5.
4	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
5	Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
6	Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. Biochem Pharmacol. 2009 May 1;77(9):1522-30.
7	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
8	Effects of FK224, a novel compound NK1 and NK2 receptor antagonist, on airway constriction and airway edema induced by neurokinins and sensory nerv... J Pharmacol Exp Ther. 1992 Jul;262(1):403-8.
9	Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J. 2004 Jan;23(1):76-81.
10	Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am J Respir Crit Care Med. 2007 Mar 1;175(5):450-7.
11	Pharmacokinetics and metabolism of a sulphamide NK2 antagonist in rat, dog and human. Xenobiotica. 2000 Jun;30(6):627-42.
12	Pharmacologic evaluation of neurokinin-2 receptor antagonists in the guinea pig respiratory tract. Am J Vet Res. 2004 Jul;65(7):984-91.
13	Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorg Med Chem. 2008 Sep 1;16(17):8301-13.
14	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and pros... J Med Chem. 2004 Dec 30;47(27):6716-29.